Financials and Corporate

Number of shares and voting rights of Innate Pharma as at July 17, 2019

July 25, 2019

Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “AMF”) charter, Innate...

Innate Pharma announces intention to conduct a registered offering in the United States

June 12, 2019

Innate Pharma, S.A. (Euronext Paris: IPH) today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares (“ADSs”), in the...

Outcome of Annual General Meeting of May 22, 2019

May 23, 2019

Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took place on May 22, 2019, in Marseille, France. All...

Innate Pharma First Quarter 2019 Report

May 15, 2019

Cash, cash equivalents and financial assets of the Company amounted to €237.1 million* Initiation of cohort expansion study of monalizumab and cetuximab to evaluate triple combination with an anti-PD...

Innate Pharma to hold its Annual General Meeting of Shareholders on May 22, 2019 and the release of its 2018 Reference Document (in French)

May 1, 2019

Innate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on May 22, 2019, at 11:00 AM in its headquarters, 117 avenue de Luminy...

Annual general meeting documents 2019

The Annual General Meeting will be convened on May 22, 2019 at 11 AM at the Company’s registered office, in Marseille.

Read more about Annual general meeting documents 2019

2018 financial results and business update: landmark deal with AstraZeneca to support transition into a fully integrated oncology-focused biotech, strong clinical progress in lead assets

March 20, 2019

Cash, cash equivalents and financial assets* amounted to €202.7m (million euros) as of December 31, 2018 (€176.6m in 2017) Revenue and other income amounted to €94.0m (€36.2m in 2017) Operating...

Subscribe to Financials and Corporate

Company
Science
Products
- Pipeline overview
- ------------------
- Lacutamab
- IPH4502
- Monalizumab
- Other Clinical Stage Assets
  - IPH6501
  - IPH6101
  - IPH6401
  - IPH5201
  - IPH5301
Partnering
Investors
Media
Careers